Liquidia Technologies is trading 34.05% up at $35.94 after announcing a global settlement with United Therapeutics on October 13, 2026, resolving six lawsuits and securing continued commercialization of YUTREPIA for pulmonary arterial hypertension. - Liquidia will pay a net $380.7 million in installments through 2027 and agreed to drop the PH-ILD indication. - Reuters reported a nearly 40% premarket jump following the settlement.